A Study of Evacetrapib and Rifampin in Healthy Participants

Lilly

Status and phase: Completed; Phase 1

Conditions: Healthy Volunteers

Treatments: Drug: Rifampin; Drug: Evacetrapib

Study type: Interventional

Funder types: Industry

Identifiers

NCT01908582

14636

I1V-MC-EIAZ (Other Identifier)

Details and patient eligibility

About

The main purpose of this study is to determine how much evacetrapib gets into the blood stream and how long it takes the body to get rid of it when given with rifampin. The safety and tolerability of the two drugs, given together, will also be evaluated. The study will also look at blood cholesterol levels and levels of a hormone called cortisol before and after taking rifampin. Information about any side effects that may occur will also be collected.

For each participant, this study will include 2 periods in fixed order. The study will last approximately 29 days.

Enrollment: 26 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Overtly healthy males and females (of non child-bearing potential)
• Have a body mass index of 18 to 32 kilograms per square meter (kg/m^2), inclusive, at screening

Exclusion criteria

• Have known allergies to evacetrapib, rifampin, related compounds or any components of either formulation, or history of significant allergic disease as determined by the investigator

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

26 participants in 2 patient groups

Evacetrapib

Experimental group

Description:

Period 1: 130 milligram (mg) evacetrapib administered orally, once on Day 1

Treatment:

Drug: Evacetrapib

Evacetrapib + Rifampin

Experimental group

Description:

Period 2: Rifampin: 600 mg administered orally, once daily (QD) for 14 days (Days 9 to 22) Evacetrapib: 130 mg administered orally once on Day 16

Treatment:

Drug: Evacetrapib

Drug: Rifampin